Intech Investment Management LLC Acquires 6,803 Shares of Kymera Therapeutics, Inc. $KYMR

Intech Investment Management LLC lifted its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 46.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,514 shares of the company’s stock after purchasing an additional 6,803 shares during the period. Intech Investment Management LLC’s holdings in Kymera Therapeutics were worth $1,674,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Kymera Therapeutics by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after purchasing an additional 1,833 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Kymera Therapeutics by 340.4% during the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after buying an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after buying an additional 491,737 shares in the last quarter. Invesco Ltd. boosted its holdings in Kymera Therapeutics by 13.8% in the 2nd quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock worth $2,090,000 after buying an additional 5,809 shares during the period. Finally, Sei Investments Co. bought a new position in Kymera Therapeutics in the 2nd quarter worth $265,000.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Jefferies Financial Group began coverage on Kymera Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $110.00 target price on the stock. Citigroup upped their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Piper Sandler lifted their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Finally, UBS Group boosted their target price on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $118.10.

Insiders Place Their Bets

In related news, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $81.18, for a total value of $2,435,400.00. Following the transaction, the chief executive officer owned 666,195 shares of the company’s stock, valued at $54,081,710.10. This represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bruce Booth sold 5,900 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total value of $530,764.00. Following the transaction, the director owned 5,641 shares in the company, valued at approximately $507,464.36. This represents a 51.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 260,115 shares of company stock worth $21,218,138. 15.98% of the stock is owned by company insiders.

Kymera Therapeutics Price Performance

Shares of KYMR stock opened at $74.61 on Friday. Kymera Therapeutics, Inc. has a 1 year low of $36.65 and a 1 year high of $103.00. The stock’s 50 day simple moving average is $83.11 and its two-hundred day simple moving average is $79.73. The company has a market cap of $6.14 billion, a PE ratio of -20.90 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. During the same period in the previous year, the company earned ($0.82) EPS. The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. Equities research analysts expect that Kymera Therapeutics, Inc. will post -3.3 EPS for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.